FibroBiologics Files 8-K: Agreements, Equity Sales
Ticker: FBLG · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1958777
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, corporate-action
TL;DR
FibroBiologics signed a new deal, terminated another, and sold some stock. Details TBD.
AI Summary
On December 19, 2024, FibroBiologics, Inc. entered into a material definitive agreement with an undisclosed party. The company also reported on the termination of a material definitive agreement and disclosed unregistered sales of equity securities. Specific details regarding the nature of these agreements and the equity sales were not provided in this initial filing.
Why It Matters
This filing indicates significant corporate activity, including new agreements and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements and unregistered equity sales, which can introduce financial and operational risks if not managed properly.
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into on December 19, 2024?
The filing does not specify the nature or counterparty of the material definitive agreement entered into on December 19, 2024.
What was the reason for the termination of the material definitive agreement?
The filing states that a material definitive agreement was terminated, but it does not provide the reason for the termination.
What type of equity securities were sold in the unregistered sale?
The filing reports unregistered sales of equity securities but does not specify the type of securities sold.
Were there any financial implications associated with the new agreement or the terminated agreement?
The filing does not disclose specific financial implications of the new or terminated material definitive agreements.
What is the total number of equity securities sold in the unregistered sale?
The filing mentions unregistered sales of equity securities but does not provide the quantity of securities sold.
Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 10.1 · Accepted 2024-12-20 17:15:33
Key Financial Figures
- $0.00001 — ichregistered Common stock, par value $0.00001 per share FBLG Nasdaq Global Marke
- $2.0 million — is obligated to pay a commitment fee of $2.0 million on the earlier of January 31, 2025 or t
- $2.17 — ued to GEM at a fixed purchase price of $2.17 per share (the "Notice"); (ii) a clos
- $2.5 million — hares at an aggregate Purchase Price of $2.5 million (the "Final Payment"); (iii) in satis
- $1.5 m — the GEM SPA for an aggregate amount of $1.5 million, and the Company's acceptance of
- $1.5 million — mmitment Fee for an aggregate amount of $1.5 million; and (b) termination of the Warrant in
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 33KB
- 0001493152-24-051109.txt ( ) — 257KB
- fblg-20241219.xsd (EX-101.SCH) — 3KB
- fblg-20241219_lab.xml (EX-101.LAB) — 33KB
- fblg-20241219_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: December 20, 2024 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer